STAMFORD, Conn., Dec. 17, 2024 /PRNewswire/ — Neuvotion, Inc. is an early-stage medical device company developing AI-driven neuromodulation technologies and products for use in the neurorehabilitation, brain-computer interface (BCI), and physical therapy markets. Today Neuvotion has…
Neuro
RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS) announced that the United States Food and Drug Administration (FDA) agreed that RapidPulse can begin enrollment in an Investigational Device Exemption (IDE) study of its novel and precise cyclic aspiration system. This will allow U.S. and European patient enrollment in 2025 to commence in a study designed to demonstrate the RapidPulse patented method of precisely pulsed aspiration is safe and effective in the treatment of AIS. RapidPulse’s technology is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.
Balt Announces Publication in New England Journal of Medicine of The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM) for the Treatment of chronic Sub-Dural Hematoma
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. STEM is the first randomized prospective IDE trial investigating embolization of the MMA for the treatment of cSDH.
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone
NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more than 25,000 procedures in the registry. This significant milestone underscores […]
Adena Health hospital recognized nationally for quality in heart and stroke care
CHILLICOTHE, Ohio, Nov. 19, 2024 /PRNewswire/ — When something doesn’t feel right, you need expert care that’s close to home. Adena Health understands this, and that is why the experts with the Adena Heart and Vascular Institute and Adena Orthopedic and Spine Institute strive to deliver…
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position
RapidAI’s leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 30, 2024 /PRNewswire/ — Recently Frost & Sullivan researched the…
The 21st World Congress of Chinese Medicine – Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris
PAIRS, Oct. 28, 2024 /PRNewswire/ — On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the…
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability
NANJING, China, Oct. 25, 2024 /PRNewswire/ — On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with…
Remedy Pharmaceuticals Announces FDA Orphan Drug Designation Granted for the Treatment of Large Territory Acute Ischemic Stroke with CIRARA
NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…



